|
|
Interleukin-7 |
|
Vaxjo ID |
57 |
|
Vaccine Adjuvant Name |
Interleukin-7 |
|
Adjuvant VO ID |
VO_0001299
|
|
Description |
adjuvant interleukin-7 (IL-7) improves antitumor responses and survival in an animal model. The improved immune response is associated with increased IL-6 production and augmented T helper type 17 cell differentiation (Pellegrini et al., 2009). |
|
Stage of Development |
Clinical Trial |
|
Dosage |
In a study, mice received daily intraperitoneal injections of 5 μg human recombinant IL-7 (rIL-7; Cytheris, Issy-les-Moulineaux, France) during the priming phase (Colombetti et al., 2009). |
|
Function |
Interleukin 7 (IL-7) stimulates the proliferation of B cell progenitors, thymocytes, and mature T cells through an interaction with a high affinity receptor (IL-7R) belonging to the hematopoietin receptor superfamily (Peschon et al., 1994). |
| Related Vaccine(s) |
|
| References |
Colombetti et al., 2009: Colombetti S, Lévy F, Chapatte L. IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector. Blood. 2009; 113(26); 6629-6637. [PubMed: 19383968].
Pellegrini et al., 2009: Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, Dhanji S, Nguyen LT, Gronski MA, Morre M, Assouline B, Lahl K, Sparwasser T, Ohashi PS, Mak TW. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nature medicine. 2009; 15(5); 528-536. [PubMed: 19396174].
Peschon et al., 1994: Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, Meyer JD, Davison BL. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. The Journal of experimental medicine. 1994; 180(5); 1955-1960. [PubMed: 7964471].
|
|
